(Q39221674)

10 September 2017

Busting robustness: using cancer's greatest strength to our advantage (English)

1 reference

10 September 2017

1

Jason R Westin

1 reference

PubMed ID

24673642

10 September 2017

language of work or name

English

0 references

publication date

1 January 2015

1 reference

10 September 2017

1 reference

10 September 2017

11

1 reference

10 September 2017

73-77

1 reference

10 September 2017

1

1 reference

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

10 September 2017

1 reference

It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy

21 January 2018

1 reference

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

21 January 2018

1 reference

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

Statistical mechanics of complex networks

21 January 2018

1 reference

Error and attack tolerance of complex networks

21 January 2018

1 reference

Diameter of the World-Wide Web

21 January 2018

1 reference

Hierarchical organization of modularity in metabolic networks

21 January 2018

1 reference

Scale-free networks and sexually transmitted diseases: a description of observed patterns of sexual contacts in Britain and Zimbabwe

21 January 2018

1 reference

ARACNE: An Algorithm for the Reconstruction of Gene Regulatory Networks in a Mammalian Cellular Context

21 January 2018

1 reference

21 January 2018

Cancer genome landscapes

1 reference

Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options

21 January 2018

1 reference

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance

21 January 2018

1 reference

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib

21 January 2018

1 reference

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.14.49

1 reference

release_pvcb33f3rnhe3cppwh4iyl3rxq

10 September 2017

0 references

PubMed ID

24673642

1 reference

PubMed ID

24673642